TABLE IV.
Baseline* predictors of week 130 desensitization success
| Predictor | n/N (%) | Univariate | Multivariate (treatment-adjusted) | ||
|---|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | ||
| Age at start of active treatment (y)† | 69/69 (100.0) | 0.63 (0.46–0.85) | .0030 | 0.67 (0.50–0.90) | .007 |
| Sex | |||||
| Male (reference) | 42/69 (60.9) | 1 | — | 1 | — |
| Female | 27/69 (39.1) | 0.73 (0.22–2.42) | .6039 | 0.75 (0.21–2.63) | .649 |
| Race | |||||
| White (reference) | 59/69 (85.5) | 1 | — | 1 | — |
| Nonwhite | 10/69 (14.5) | 2.91 (0.70–12.09) | .1418 | 3.92 (0.78–19.81) | .098 |
| Asthma | |||||
| No (reference) | 33/69 (47.8) | 1 | — | 1 | — |
| Yes | 36/69 (52.2) | 0.53 (0.17–1.71) | .2899 | 0.39 (0.11–1.37) | .143 |
| Allergic rhinitis | |||||
| No (reference) | 14/69 (20.3) | 1 | — | 1 | — |
| Yes | 55/69 (79.7) | 1.86 (0.37–9.39) | .4542 | 2.32 (0.43–12.46) | .326 |
| Atopic dermatitis | |||||
| None (reference) | 46/69 (66.7) | 1 | — | 1 | — |
| Mild/moderate/severe | 23/69 (33.3) | 1.00 (0.30–3.37) | 1.0000 | 0.98 (0.27–3.52) | .975 |
| Atopic dermatitis score | 69/69 (100.0) | 1.00 (0.78–1.30) | .9725 | 1.00 (0.76–1.31) | 1.000 |
| Log10 peanut IgE | 69/69 (100.0) | 0.89 (0.37–2.15) | .7964 | 0.88 (0.35–2.23) | .789 |
| Log10 Ara h1 IgE | 69/69 (100.0) | 0.82 (0.55–1.23) | .3395 | 0.86 (0.56–1.31) | .480 |
| Log10 Ara h2 IgE | 69/69 (100.0) | 0.86 (0.39–1.87) | .6993 | 0.81 (0.36–1.81) | .601 |
| Log10 Ara h3 IgE | 69/69 (100.0) | 0.75 (0.46–1.24) | .2603 | 0.76 (0.44–1.30) | .309 |
| Log10 total IgE | 69/69 (100.0) | 2.07 (0.54–7.99) | .2890 | 2.12 (0.52–8.70) | .295 |
| Peanut IgG4 | 69/69 (100.0) | 0.64 (0.22–1.81) | .3968 | 0.81 (0.25–2.62) | .727 |
| Log10 Ara h1 IgG4 | 69/69 (100.0) | 0.59 (0.28–1.27) | .1783 | 0.61 (0.26–1.45) | .263 |
| Log10 Ara h2 IgG4 | 69/69 (100.0) | 0.54 (0.20–1.48) | .2340 | 0.50 (0.16–1.63) | .253 |
| Log10 Ara h3 IgG4 | 69/69 (100.0) | 0.41 (0.16–1.06) | .0661 | 0.48 (0.18–1.31) | .153 |
| Peanut %IgE | 69/69 (100.0) | 0.97 (0.92–1.01) | .1674 | 0.97 (0.92–1.02) | .189 |
| Ratio IgG4/IgE | 69/69 (100.0) | 0.82 (0.34–1.98) | .6572 | 0.99 (0.39–2.53) | .990 |
| Peanut SPT score (mm) | 69/69 (100.0) | 1.02 (0.94–1.12) | .5934 | 1.04 (0.94–1.14) | .446 |
SPT, Skin prick test.
*
Baseline values used for PLB-VP250 subjects are from week 52.
†
Median (IQR) age at start of active treatment was 6.2 (5.2–9.1) y in week 130 desensitization successes and 9.4 (7.6–12.8) y in failures (P = .0005).